Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low but detectable HIV viremia and undetectable HIV vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Basso, Monica, Battagin, Giuliana, Nicolè, Stefano, Rossi, Maria Cristina, Colombo, Francesco, Pirola, Nicole, Baratti, Stefano, Storato, Silvia, Giovagnorio, Federico, Malagnino, Vincenzo, Alessio, Grazia, Vinci, Antonio, Maurici, Massimo, Sarmati, Loredana, Parisi, Saverio Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458950/
https://www.ncbi.nlm.nih.gov/pubmed/37632071
http://dx.doi.org/10.3390/v15081727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458950/
https://www.ncbi.nlm.nih.gov/pubmed/37632071
http://dx.doi.org/10.3390/v15081727

Ejemplares similares